Letter to the editor on “Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial” by Udwadia et al

[저자] Mahender Kumar Medisetty, Atul Patel, Sanjay Pujari

[Category] SARS, 임상,

[Article Type] Correspondence

[Source] Sciencedirect

All Keywords
【제목키워드】 Open-label, Favipiravir, Randomized, RNA-dependent RNA polymerase, multicenter, inhibitor, Phase 3, Mild-to-moderate,